CLINICAL TRIALS PROFILE FOR BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

All Clinical Trials for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00452972 ↗	Exteriorized Versus In Situ Uterine Repair at Cesarean Delivery	Completed	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	N/A	2004-04-01	This study was undertaken to compare the two techniques (exteriorized vs in situ) of uterine repair with respect to patient comfort, hemodynamic changes, surgical time and blood loss, in patients undergoing elective CD under a strictly standardized spinal anesthetic. We hypothesized that in situ uterine repair would be more comfortable for the patients.
NCT00486902 ↗	Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?	Completed	Northwestern University	N/A	2006-07-01	Pain control after cesarean delivery is associated with improved breastfeeding and infant rooming-in times. In addition, inadequate analgesia leads to elevated plasma catecholamine concentrations, which negatively affect every organ system. There is growing evidence that ketamine, N-methyl-D-aspartate receptor antagonist, is efficacious when used as an adjuvant in postoperative pain control. A 2006 Cochrane Collaboration systemic review and meta-analysis concluded, "Ketamine in subanesthetic doses….is effective in reducing morphine requirements in the first 24 hours after surgery." Ketamine's prolonged analgesic effect, despite its short half-life and its use in low doses, is theorized to be due to blockade of spinal cord central sensitization. Central sensitization is a phenomenon whereby repeated painful stimulus leads to more severe pain perception over time despite no change in the intensity of the painful stimulus.Ketamine may also prevent the development of acute opioid tolerance. Ketamine's analgesic effects have also demonstrated in the obstetric population. Post-cesarean delivery morphine requirements in women who received ketamine as part of a general anesthesia technique were decreased. Similary, low-dose ketamine in conjunction with bupivacaine-only spinal anesthesia reduced postoperative analgesic requirements compared to bupivacaine-only spinal anesthesia and bupivacaine-fentanyl spinal anesthesia. In the United States, healthy women scheduled for elective cesarean delivery commonly receive spinal anesthesia with bupivacaine-fentanyl-morphine. To our knowledge, IV ketamine has not been studied as an adjuvant to this regimen in the analgesic management in post-cesarean delivery patients. Multimodal therapy for postoperative pain control is widely practiced due to the advantage it provides in blocking multiple pain pathways while minimizing side effects of each individual pain medication. We hypothesize that low dose intravenous ketamine will improve multi-modal post-cesarean analgesia compared to placebo. The purpose of this study is to evaluate this hypothesis and study the possible side effects of this regimen in combination with bupivacaine-fentanyl-morphine spinal anesthesia.
NCT00635986 ↗	Analgesic Effect and Plasma Concentration of Epidural Versus Intravenous Fentanyl	Completed	Federal University of São Paulo	N/A	2004-05-01	CONTEXT AND OBJECTIVE: Controversies exist regarding the site of action of Fentanyl after epidural injection. The objective of this investigation was to compare the analgesic effect of epidural and intravenous Fentanyl for lower limb orthopedic surgeries. DESIGN AND SETTING: A randomized and double-blind study was performed in Hospital São Paulo. METHODS: 29 patients were divided into two groups. During the postoperative period, in the presence of pain, group 1 (n = 14) patients received 5 mL of a 100 mcg Fentanyl solution in saline without preservative by the epidural route and 2 mL saline intravenously. Group 2 (n = 15) patients received 5 mL saline by the epidural route and 2 mL (100 mcg) Fentanyl intravenously. Analgesic supplementation consisted of 40 mg intravenous Tenoxicam and 5 mL epidural 0.25% bupivacaine (if pain relief was not achieved with Tenoxicam). Pain intensity was evaluated by numerical scale and plasma concentrations of Fentanyl were measured simultaneously.
NCT00845962 ↗	A Comparison of Bupivacaine and 2-chloroprocaine for Spinal Anesthesia	Completed	Centre hospitalier de l'Université de Montréal (CHUM)	N/A	2009-02-01	The purpose of this study is to compare the efficacity and the readiness for discharge between two local anesthetics, bupivacaine and 2-chloroprocaine, used for spinal anesthesia.
NCT00845962 ↗	A Comparison of Bupivacaine and 2-chloroprocaine for Spinal Anesthesia	Completed	Université de Montréal	N/A	2009-02-01	The purpose of this study is to compare the efficacity and the readiness for discharge between two local anesthetics, bupivacaine and 2-chloroprocaine, used for spinal anesthesia.
NCT01055236 ↗	Hydroxyzine for the Prevention of Pruritus From Spinal Morphine in Transabdominal Hysterectomy Patients	Completed	Mahidol University	Phase 4	2007-08-01	Hydroxyzine is one of antihistamines that antagonizes H1 receptor, and it's effects are reducing pruritus, nausea/vomiting, and the mild effect of sedation.With these effects Hydroxyzine should be used in the prevention of these symptoms.

Clinical Trial Conditions for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

Condition Name

Condition Name for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE
Intervention	Trials
Pain	7
Pain, Postoperative	5
Post Operative Pain	4
Nausea	3

Condition MeSH

Condition MeSH for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE
Intervention	Trials
Pain, Postoperative	13
Hypotension	5
Vomiting	4
Nausea	4

Clinical Trial Locations for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

Trials by Country

Trials by Country for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE
Location	Trials
United States	48
Egypt	8
Canada	6
Ireland	2
Pakistan	2

Trials by US State

Trials by US State for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE
Location	Trials
Pennsylvania	4
North Carolina	4
New York	4
California	4
Texas	3

Clinical Trial Progress for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

Clinical Trial Phase

Clinical Trial Phase for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	1
Phase 4	30

Clinical Trial Status

Clinical Trial Status for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE
Clinical Trial Phase	Trials
Completed	30
Recruiting	15
Unknown status	8

Clinical Trial Sponsors for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

Sponsor Name

Sponsor Name for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE
Sponsor	Trials
Pacira Pharmaceuticals, Inc	4
University of Manitoba	4
Cairo University	3

Sponsor Type

Sponsor Type for BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE
Sponsor	Trials
Other	62
Industry	5

Bupivacaine Hydrochloride Preservative Free: Clinical Trial Signal, Market Read-Through, and Revenue Projection

Last updated: April 28, 2026

What is bupivacaine hydrochloride preservative free and where is it used clinically?

Bupivacaine hydrochloride preservative free is a local anesthetic formulation used for regional anesthesia where product sterility and reduced excipient exposure are clinically relevant, including:

• Peripheral nerve blocks (upper and lower extremity)
• Epidural anesthesia and analgesia
• Local infiltration anesthesia and surgical field anesthesia
• Postoperative pain management and chronic pain procedures (where indicated by local labeling and guideline practice)

Commercially, the product is positioned as a preservative-free injectable option, typically supplied in vial and/or cartridge/ampul presentations depending on brand and market.

What clinical trial activity is visible for this drug class (and how to read it for the preservative-free segment)?

A full, current “trial-by-trial” update for the exact phrase “bupivacaine hydrochloride preservative free” requires database-level visibility (trial registry IDs, sponsor names, trial phases, and endpoints). Under the constraints here, no validated, citable clinical trial dataset is available in the prompt context to produce an audit-ready update.

That said, the clinical development pattern for bupivacaine products generally falls into four buckets that drive regulatory and commercial value:

1. Dose and concentration optimization for specific blocks
2. Onset and duration comparisons against other local anesthetics and formulations
3. Safety and tolerability studies (especially neurologic and cardiovascular risk minimization via formulation, handling, and dosing)
4. Combination regimens (adjuvants) where bupivacaine remains the core active

For investment-grade read-through: the preservative-free attribute tends to be a formulation advantage rather than a distinct mechanism driver, so late-phase novelty usually comes from delivery system, dosing regime, or comparative efficacy claims, not from a new pharmacology profile.

Market analysis: demand drivers for preservative-free bupivacaine

Who buys and why

In developed markets, demand comes primarily from:

• Hospital and ambulatory surgery centers using regional anesthesia protocols
• Anesthesia departments running standardized block pathways
• Pain management clinics using local anesthetic procedures

Purchasing behavior is shaped by:

• Clinical protocol standardization (preferred formulations per pathway)
• Formulary contracting and tender cycles
• Inventory control needs (single-use preservative-free aligns with safety and handling preferences in peri-procedural workflows)

Commercial supply dynamics

This segment faces typical local anesthetic market dynamics:

• Generic substitution pressure where patent protection is weak
• Brand retention where substitution is constrained by:
  • Hospital formulary decisions
  • Product availability and supply reliability
  • Presentation-specific use cases (vial sizes, concentration availability)

Pricing and reimbursement read-through

Across US and EU markets, pricing for local anesthetics often follows a downward trajectory post-competition, with preservative-free products maintaining price strength when:

• Substitution is limited by procurement rules
• Product is bundled in clinical pathways
• Hospitals perceive operational or safety advantages tied to preservative-free supply

Market projection framework

Because the prompt does not include:

• current global sales,
• unit volumes by concentration/presentation,
• brand-level pricing,
• or trial-registered commercial timelines, a strict, citable projection cannot be produced without creating unsupported assumptions.

So the projection below is presented as a structured scenario map rather than a claimed point forecast. It translates market mechanics into an actionable planning model: what affects growth, what caps growth, and what milestones move the curve.

What drives growth versus decline in preservative-free bupivacaine?

Growth drivers

• Expansion of regional anesthesia adoption over general anesthesia where guidelines support it
• Increased use of postoperative pain pathways using blocks and infiltration
• Hospital conversion to single-use, preservative-free workflows
• New contracting outcomes that favor preservative-free SKUs (tender wins, preferred formulary placement)

Decline or drag factors

• Generic entry and interchangeability pressure
• Tender-driven price compression
• Supply constraints and substitution to alternative local anesthetic brands or concentrations
• Clinician preference shifts toward alternative anesthetics and delivery systems

Revenue projection scenarios (planning-grade model)

Scenario definitions

This model uses three levers to translate market events into commercial outcomes:

• Volume CAGR (procedure growth and formulary mix)
• Net price CAGR (tender and competition impact)
• Share capture (brand or product SKU retention vs generic substitution)

Base case logic (no new exclusivity assumed)

• Volume: grows in line with regional anesthesia usage and procedural volume recovery
• Price: trends modestly down due to competition and formulary pressure
• Net revenue: grows at a slower rate than volume because of price erosion

Upside case logic (preferred formulary capture)

• Product retains or gains share in major hospital systems
• Preservative-free SKU becomes default in block pathways
• Price erosion is limited by contracting stickiness and supply reliability

Downside case logic (aggressive competition)

• Broader generic substitution and tender wins by lower-cost equivalents
• Shift from specific presentations (vials/concentrations) to competitors with better procurement economics

Actionable implications for R&D, licensing, and investment

If you are underwriting an R&D strategy

For bupivacaine preservative-free, value creation usually requires one of:

• Clinical differentiation via comparative efficacy and operational endpoints (time to block, duration of analgesia, protocol success rates)
• Product differentiation via presentation and usability (single-use, dose standardization, reduced handling errors)
• Regulatory differentiation via clearly framed claim sets tied to preservative-free handling benefits, where label language supports it

Without a clear novel mechanism, clinical programs that depend only on “newness” without measurable advantage typically struggle to overcome tender-driven pricing pressure.

If you are underwriting a licensing or portfolio decision

Acquisition or licensing should prioritize:

• Contracted hospital penetration and tender history for preservative-free SKUs
• Supply continuity and packaging compatibility with anesthesia workflows
• Concentration and presentation breadth that matches commonly used block protocols

Key decision checklist for investors and product planners

• Is preservative-free required by formulary or pathway in target accounts?
• Does the brand hold a presentation that clinicians standardize on?
• What is the expected price trajectory given the competitive setup (generic substitution risk)?
• Are there demonstrable outcomes tied to preservative-free workflows (handling, compliance, protocol adherence)?

---

Key Takeaways

• Bupivacaine hydrochloride preservative free is a formulation-driven segment within local anesthesia used for regional and perioperative pain workflows.
• Clinical trial activity for this exact product phrase cannot be enumerated with audit-ready specificity from the provided context, but development patterns in bupivacaine products typically emphasize block-specific dosing, comparative performance, and safety/tolerability.
• Market growth depends more on regional anesthesia adoption and hospital formulary mix than on mechanism novelty.
• Revenue outcomes are dominated by net price erosion from generics and tender cycles versus share retention in preferred formulary accounts.
• For projections, underwriting should be built on volume CAGR, net price CAGR, and share capture, with scenarios reflecting procurement realities.

FAQs

1. Is preservative-free bupivacaine clinically differentiated from standard bupivacaine?
   It is differentiated as a preservative-free formulation used where hospital protocols and handling preferences favor that attribute, especially in peri-procedural workflows.

2. What endpoints matter most for bupivacaine product differentiation in trials?
   Block success rate, time to onset, duration of analgesia, and safety/tolerability metrics tied to dosing and procedure type.

3. How do generic and tender dynamics typically affect this market?
   They compress net pricing after competition, so revenue growth depends on share retention and formulary placement rather than pricing.

4. Which clinical settings purchase most preservative-free local anesthetics?
   Hospitals and ambulatory surgery centers, followed by pain management and procedural clinics that run standardized block pathways.

5. What is the highest-leverage commercial strategy for a preservative-free SKU?
   Achieve and maintain preferred formulary status in high-volume accounts and maintain supply reliability aligned with standardized anesthesia protocols.

---

References

[1] FDA Drug Labels (Local anesthetics and bupivacaine product prescribing information). American Medical Association / FDA label repository.
[2] ClinicalTrials.gov. “Bupivacaine” search and related entries (trial endpoints and design patterns).
[3] World Health Organization. Regional anesthesia and perioperative pain management clinical guidance documents (for utilization context).